VEA
PRME icon

Virtus ETF Advisers’s Prime Medicine PRME Stock Holding History

Virtus ETF Advisers’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,618
Closed -$69K – 698
2024
Q4 		$69K Buy
23,618
+11,948
+102% +$41.9K 0.03% 385
2024
Q3 		$45.2K Buy
11,670
+211
+2% +$977 0.02% 443
2024
Q2 		$58.9K Buy
+11,459
New +$69.5K 0.03% 440

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Virtus ETF Advisers's PRME Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Prime Medicine (PRME) in Q1 2025, closing a stake of 23,618 shares — an estimated $69K sold.

Virtus ETF Advisers first reported a position in PRME in Q2 2024 and held it in 3 quarters. The position peaked at $69K in Q4 2024. 125 funds tracked by Wall St. Rank hold PRME as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Prime Medicine position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 23,618 Prime Medicine shares in Q1 2025, an estimated $69K.
  • Virtus ETF Advisers first reported a position in Prime Medicine in Q2 2024 and held it in 3 quarters.
  • Virtus ETF Advisers's Prime Medicine position peaked at $69K in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.